Loading...

Mack Roach, III, MD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentRadiation Oncology
Address1600 Divisadero
San Francisco CA 94115
Phone415-353-7110
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford UniversityM.D.1979School of Medicine

    Collapse Research 
    Collapse Research Activities and Funding
    NAPTA: Optimizing clinical trial design & delivery of particle therapy for cancer
    NIH/NCI P20CA183640Feb 10, 2015 - Jan 31, 2017
    Role: Principal Investigator
    SFSU/UCSF Comprehensive Cancer Partnership Program
    NIH/NCI U56CA096216Jul 1, 2002 - Jun 30, 2010
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2017 Jun 24. PMID: 28655541.
      View in: PubMed
    2. Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M, Kwok Y, Dignam JJ, Sandler HM. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Jun 01; 98(2):296-303. PMID: 28463149.
      View in: PubMed
    3. Gandaglia G, Briganti A, Clarke N, Karnes RJ, Graefen M, Ost P, Zietman AL, Roach M. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol. 2017 Feb 08. PMID: 28189428.
      View in: PubMed
    4. Zhang L, Johnson J, Gottschalk AR, Chang AJ, Hsu IC, Roach M, Seymour ZA. Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2017 Mar - Apr; 7(2):e109-e116. PMID: 28274401.
      View in: PubMed
    5. Wahl M, Descovich M, Shugard E, Pinnaduwage D, Sudhyadhom A, Chang A, Roach M, Gottschalk A, Chen J. Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer. Technol Cancer Res Treat. 2017 Apr; 16(2):178-187. PMID: 27199276.
      View in: PubMed
    6. Roach M. Prostate cancer: Combining endocrine treatment and radiotherapy: a bright future. Nat Rev Urol. 2016 Jul; 13(7):373-4. PMID: 27245503.
      View in: PubMed
    7. Roach M. Surgery Provides Better Oncologic Outcomes than Radiation for the Treatment of Prostate Cancer. J Urol. 2016 Aug; 196(2):308-9. PMID: 27164515.
      View in: PubMed
    8. Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M. Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery. Am J Clin Oncol. 2016 Apr; 39(2):167-72. PMID: 24441584.
      View in: PubMed
    9. Pinnaduwage DS, Descovich M, Lometti MW, Varad B, Roach M, Gottschalk AR. An Evaluation of Robotic and Conventional IMRT for Prostate Cancer: Potential for Dose Escalation. Technol Cancer Res Treat. 2017 Jun; 16(3):267-275. PMID: 27037301.
      View in: PubMed
    10. Chan J, Roach M. Words of Wisdom. Re: Genomic Classifier Identifies Men with Adverse Pathology After Radical Prostatectomy Who Benefit from Adjuvant Radiation Therapy. Eur Urol. 2016 Mar; 69(3):539-40. PMID: 26867726.
      View in: PubMed
    11. Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M, Gottschalk AR. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol. 2016 Jan 21; 11:8. PMID: 26792201; PMCID: PMC4721063.
    12. Roach M, Schulte R, Mishra K, Faddegon B, Barani I, Lazar A, Blakely EA. New Clinical and Research Programs in Particle Beam Radiation Therapy: The University of California San Francisco Perspective. Int J Part Ther. 2016; 2(3):471-473. PMID: 27099866.
      View in: PubMed
    13. Chen CP, Johnson J, Seo Y, Weinberg VK, Shinohara K, Hsu IJ, Roach M. Sentinel lymph node imaging guided IMRT for prostate cancer: Individualized pelvic radiation therapy versus RTOG guidelines. Adv Radiat Oncol. 2016 Jan-Mar; 1(1):51-58. PMID: 28799574.
      View in: PubMed
    14. Roach M, Ceron Lizarraga TL, Lazar AA. Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy for Clinically Localized Prostate Cancer: How Good Is the Evidence? Int J Radiat Oncol Biol Phys. 2015 Dec 01; 93(5):1064-70. PMID: 26581143.
      View in: PubMed
    15. Kaplan CP, Nápoles AM, Narine S, Gregorich S, Livaudais-Toman J, Nguyen T, Leykin Y, Small EJ. Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients. Contemp Clin Trials. 2015 Nov; 45(Pt B):443-448. PMID: 26435199.
      View in: PubMed
    16. Raleigh DR, Chang AJ, Tomlin B, Cunha JA, Braunstein SE, Shinohara K, Gottschalk AR, Roach M, Hsu IC. Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer. Brachytherapy. 2015 Nov-Dec; 14(6):795-800. PMID: 26198421.
      View in: PubMed
    17. Pisansky TM, Suman VJ, Roach M, Sandler HM. Reporting of results in DART01/05 GICOR. Lancet Oncol. 2015 Jun; 16(6):e258. PMID: 26065604.
      View in: PubMed
    18. Hsu CC, Paciorek AT, Cooperberg MR, Roach M, Hsu IC, Carroll PR. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter? BJU Int. 2015 Nov; 116(5):713-20. PMID: 25600860.
      View in: PubMed
    19. Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach M, Chang AJ, Chan JM, Simko JP, Carroll PR. Patterns of Local Failure following Radiation Therapy for Prostate Cancer. J Urol. 2015 Oct; 194(4):977-82. PMID: 25983194.
      View in: PubMed
    20. Bossi A, Wiegel T, Roach M. Postprostatectomy Radiotherapy for Patients with High-risk Features on Definitive Pathology: A Plea for Evidence-based Medicine. Eur Urol. 2015 Nov; 68(5):775-6. PMID: 25976403.
      View in: PubMed
    21. Seymour ZA, Chang AJ, Zhang L, Kirby N, Descovich M, Roach M, Hsu IC, Gottschalk AR. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 Sep-Oct; 5(5):e465-72. PMID: 25795252.
      View in: PubMed
    22. Raleigh DR, Hsu IC, Braunstein S, Chang AJ, Simko JP, Roach M. Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy. Brachytherapy. 2015 Mar-Apr; 14(2):185-8. PMID: 25533416.
      View in: PubMed
    23. Hamstra DA, Bae K, Hanks G, Hu C, Shipley WU, Pan CC, Roach M, Lawton CA, Sandler HM. Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer. 2015 Mar 15; 121(6):844-52. PMID: 25410885; PMCID: PMC4657945.
    24. Roach M. Natural History after Biochemical Failure Following Dose-escalated External Beam Radiation: An Opportunity to Improve Outcomes? Eur Urol. 2015 Jun; 67(6):1017-1018. PMID: 25457015.
      View in: PubMed
    25. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M, Briganti A. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015 May; 67(5):852-63. PMID: 25240974.
      View in: PubMed
    26. Alexander J, Weinberg V, Gottschalk AR, Hsu IC, Shinohara K, Roach M. Pre-plan parameters predict post-implant D90 = 140 Gy for (125)I permanent prostate implants. J Contemp Brachytherapy. 2014 Jun; 6(2):143-53. PMID: 25097554; PMCID: PMC4105644.
    27. Chen CP, Braunstein S, Mourad M, Hsu IC, Haas-Kogan D, Roach M, Fogh SE. Quality improvement of International Classification of Diseases, 9th revision, diagnosis coding in radiation oncology: single-institution prospective study at University of California, San Francisco. Pract Radiat Oncol. 2015 Jan-Feb; 5(1):e45-51. PMID: 25413428.
      View in: PubMed
    28. Chang AJ, Autio KA, Roach M, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014 Jun; 11(6):308-23. PMID: 24840073; PMCID: PMC4508854.
    29. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May; 12(5):686-718. PMID: 24812137.
      View in: PubMed
    30. Roach M. Radium-223 vs EBRT for multiple painful bone metastases: is less more? Oncology (Williston Park). 2014 Apr; 28(4):297-8. PMID: 24839801.
      View in: PubMed
    31. Roach M. Radical prostatectomy v radiation: only a randomised trial can provide the answer. BMJ. 2014 Mar 25; 348:g2266. PMID: 24668796.
      View in: PubMed
    32. Johnson J, Roach M. Prostate cancer: impact of national guidelines on brachytherapy monotherapy. Nat Rev Urol. 2014 Apr; 11(4):195-6. PMID: 24619374.
      View in: PubMed
    33. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014; 9(3):e89754. PMID: 24594774; PMCID: PMC3940667.
    34. Roach M. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer. Cancer. 2014 Jun 01; 120(11):1620-9. PMID: 24591080.
      View in: PubMed
    35. Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, Gottschalk A. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014 Feb 02; 9:42. PMID: 24484652; PMCID: PMC3923240.
    36. Qi P, Pouliot J, Roach M, Xia P. Offline multiple adaptive planning strategy for concurrent irradiation of the prostate and pelvic lymph nodes. Med Phys. 2014 Feb; 41(2):021704. PMID: 24506595.
      View in: PubMed
    37. Anwar M, Westphalen AC, Jung AJ, Noworolski SM, Simko JP, Kurhanewicz J, Roach M, Carroll PR, Coakley FV. Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology. Radiother Oncol. 2014 Feb; 110(2):303-8. PMID: 24444524; PMCID: PMC3969841.
    38. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M. Prostate cancer, version 1.2014. J Natl Compr Canc Netw. 2013 Dec 01; 11(12):1471-9. PMID: 24335682.
      View in: PubMed
    39. Crehange G, Krishnamurthy D, Cunha JA, Pickett B, Kurhanewicz J, Hsu IC, Gottschalk AR, Shinohara K, Roach M, Pouliot J. Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: implications for focal salvage brachytherapy. Radiother Oncol. 2013 Nov; 109(2):246-50. PMID: 24231238; PMCID: PMC4081029.
    40. Descovich M, Carrara M, Morlino S, Pinnaduwage DS, Saltiel D, Pouliot J, Nash MB, Pignoli E, Valdagni R, Roach M, Gottschalk AR. Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife. J Appl Clin Med Phys. 2013 Sep 06; 14(5):162-72. PMID: 24036869.
      View in: PubMed
    41. Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, van Poppel H, Roach M, Stephenson A, Wiegel T, Zelefsky MJ. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014 Jun; 65(6):1034-43. PMID: 23972524.
      View in: PubMed
    42. Valicenti RK, Thompson I, Albertsen P, Davis BJ, Goldenberg SL, Wolf JS, Sartor O, Klein E, Hahn C, Michalski J, Roach M, Faraday MM. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):822-8. PMID: 23845839.
      View in: PubMed
    43. Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf JS, Faraday MM. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013 Aug; 190(2):441-9. PMID: 23707439.
      View in: PubMed
    44. Pan L, Baek S, Edmonds PR, Roach M, Wolkov H, Shah S, Pollack A, Hammond ME, Dicker AP. Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. Radiat Oncol. 2013 Apr 25; 8:100. PMID: 23618468; PMCID: PMC3653757.
    45. Kaidar-Person O, Roach M, Créhange G. Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: a step forward. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):600-5. PMID: 23523182.
      View in: PubMed
    46. Cury FL, Hunt D, Roach M, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C. Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer. 2013 Jun 01; 119(11):1999-2004. PMID: 23504930; PMCID: PMC3663874.
    47. Chen CP, Weinberg V, Shinohara K, Roach M, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013 Jun 01; 86(2):324-9. PMID: 23474112.
      View in: PubMed
    48. Chang AJ, Roach M. Cautious optimism for extreme dose escalation in prostate cancer. Eur Urol. 2013 Dec; 64(6):939-40. PMID: 23506832.
      View in: PubMed
    49. Pejavar S, Yom SS, Hwang A, Speight J, Gottschalk A, Hsu IC, Roach M, Xia P. Computer-assisted, atlas-based segmentation for target volume delineation in whole pelvic IMRT for prostate cancer. Technol Cancer Res Treat. 2013 Jun; 12(3):199-206. PMID: 23289478.
      View in: PubMed
    50. Roach M, Thomas K. Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? J Natl Cancer Inst Monogr. 2012 Dec; 2012(45):221-9. PMID: 23271777; PMCID: PMC3540886.
    51. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Sep; 10(9):1081-7. PMID: 22956807.
      View in: PubMed
    52. Michalski J, Winter K, Roach M, Markoe A, Sandler HM, Ryu J, Parliament M, Purdy JA, Valicenti RK, Cox JD. Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e363-70. PMID: 22633552; PMCID: PMC3361689.
    53. Créhange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, Roach M. Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev. 2012 Dec; 38(8):956-67. PMID: 22703831; PMCID: PMC3739983.
    54. Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):370-7. PMID: 22672747.
      View in: PubMed
    55. Meijer HJ, Debats OA, Roach M, Span PN, Witjes JA, Kaanders JH, van Lin EN, Barentsz JO. Magnetic resonance lymphography findings in patients with biochemical recurrence after prostatectomy and the relation with the Stephenson nomogram. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1186-91. PMID: 22520482.
      View in: PubMed
    56. Chang AJ, Roach M. Radium-223: down to the bone, and less is more. Oncology (Williston Park). 2012 Apr; 26(4):342, 344. PMID: 22655526.
      View in: PubMed
    57. Bastian PJ, Boorjian SA, Bossi A, Briganti A, Heidenreich A, Freedland SJ, Montorsi F, Roach M, Schröder F, van Poppel H, Stief CG, Stephenson AJ, Zelefsky MJ. High-risk prostate cancer: from definition to contemporary management. Eur Urol. 2012 Jun; 61(6):1096-106. PMID: 22386839.
      View in: PubMed
    58. Roach M. Long-term potency preservation following brachytherapy for prostate cancer. BJU Int. 2012 Jul; 110(2):225. PMID: 22734476.
      View in: PubMed
    59. Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M, Jung AJ, Carroll PR, Coakley FV. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):e787-93. PMID: 22331003; PMCID: PMC3285390.
    60. Hwang AB, Chen J, Nguyen TB, Gottschalk AG, Roach MR, Pouliot J. Irradiation of the prostate and pelvic lymph nodes with an adaptive algorithm. Med Phys. 2012 Feb; 39(2):1119-24. PMID: 22320822.
      View in: PubMed
    61. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012 Feb; 109 Suppl 1:22-9. PMID: 22239226.
      View in: PubMed
    62. Myrehaug S, Chan G, Craig T, Weinberg V, Cheng C, Roach M, Cheung P, Sahgal A. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Mar 15; 82(4):e657-62. PMID: 22245189.
      View in: PubMed
    63. Roach M. Editorial comment. Urology. 2011 Dec; 78(6):1367-8. PMID: 22137705.
      View in: PubMed
    64. Shiao SL, Sahgal A, Hu W, Jabbari S, Chuang C, Descovich M, Hsu IC, Gottschalk AR, Roach M, Ma L. Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapy. Phys Med Biol. 2011 Dec 21; 56(24):7767-75. PMID: 22107791.
      View in: PubMed
    65. Moul JW, Evans CP, Gomella LG, Roach M, Dreicer R. Traditional approaches to androgen deprivation therapy. Urology. 2011 Nov; 78(5 Suppl):S485-93. PMID: 22054920.
      View in: PubMed
    66. Moul JW, Kibel AS, Roach M, Dreicer R. Indications and practice with androgen deprivation therapy. Urology. 2011 Nov; 78(5 Suppl):S478-81. PMID: 22054918.
      View in: PubMed
    67. Stephenson AJ, Bolla M, Briganti A, Cozzarini C, Moul JW, Roach M, van Poppel H, Zietman A. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol. 2012 Mar; 61(3):443-51. PMID: 22036777.
      View in: PubMed
    68. Cunha JA, Pouliot J, Weinberg V, Wang-Chesebro A, Roach M, Hsu IC. Urethra low-dose tunnels: validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy. Brachytherapy. 2012 Sep-Oct; 11(5):348-53. PMID: 21937284.
      View in: PubMed
    69. Moyad MA, Roach M. Promoting wellness for patients on androgen deprivation therapy: why using numerous drugs for drug side effects should not be first-line treatment. Urol Clin North Am. 2011 Aug; 38(3):303-12. PMID: 21798392.
      View in: PubMed
    70. Roach M, Alberini JL, Pecking AP, Testori A, Verrecchia F, Soteldo J, Ganswindt U, Joyal JL, Babich JW, Witte RS, Unger E, Gottlieb R. Diagnostic and therapeutic imaging for cancer: therapeutic considerations and future directions. J Surg Oncol. 2011 May 01; 103(6):587-601. PMID: 21480253.
      View in: PubMed
    71. Kumbhani SR, Coakley FV, McCulloch CE, Wang ZJ, Kurhanewicz J, Roach M, Westphalen AC. Endorectal MRI after radiation therapy: questioning the sextant analysis. J Magn Reson Imaging. 2011 May; 33(5):1086-90. PMID: 21509865; PMCID: PMC3081102.
    72. Morikawa LK, Roach M. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys. 2011 May 01; 80(1):6-16. PMID: 21481721.
      View in: PubMed
    73. Chen CP, Staggers FE, Roach M. Benefits and pitfalls of prostate cancer screening: "no proof of benefit" does not equal "proof of no benefit". Oncology (Williston Park). 2011 May; 25(6):466, 468. PMID: 21717899.
      View in: PubMed
    74. Roach M. Editorial comment. Urology. 2011 Apr; 77(4):991-2; author reply 992-3. PMID: 21477731.
      View in: PubMed
    75. Hayes M, Roach M. Predicting the risk of pelvic node involvement in men with prostate cancer in the contemporary era: change you can believe?: in regard to Yu, et al. (Int J Radiat Oncol Biol Phys in press). Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1598; author reply 1598-9. PMID: 21414516.
      View in: PubMed
    76. Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H. Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1293-301. PMID: 21458924; PMCID: PMC4675045.
    77. Dasgupta T, Barani IJ, Roach M. Successful radiation treatment of anaplastic thyroid carcinoma metastatic to the right cardiac atrium and ventricle in a pacemaker-dependent patient. Radiat Oncol. 2011 Feb 14; 6:16. PMID: 21320341; PMCID: PMC3049119.
    78. Roach M. Editorial comment. BJU Int. 2011 Jan; 107(2):232-3. PMID: 21208366.
      View in: PubMed
    79. Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M, Gottschalk AR. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):228-34. PMID: 21183287.
      View in: PubMed
    80. Kaprealian T, Weinberg V, Speight JL, Gottschalk AR, Roach M, Shinohara K, Hsu IC. High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):222-7. PMID: 21163586.
      View in: PubMed
    81. Xia P, Qi P, Hwang A, Kinsey E, Pouliot J, Roach M. Comparison of three strategies in management of independent movement of the prostate and pelvic lymph nodes. Med Phys. 2010 Sep; 37(9):5006-13. PMID: 20964220.
      View in: PubMed
    82. Roach M. Primary focal unilateral nerve-sparing cryoablation for very early prostate cancer: is it enough or too much, or do we know? Cancer J. 2010 Sep-Oct; 16(5):542-3. PMID: 20890153.
      View in: PubMed
    83. Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H. Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. Int J Radiat Oncol Biol Phys. 2011 Jun 01; 80(2):445-52. PMID: 20615632; PMCID: PMC2952349.
    84. Hamstra DA, Michalski JM, Roach M, Sandler HM. Do not count out external-beam radiation therapy for high-risk prostate cancer. J Clin Oncol. 2010 Oct 01; 28(28):e518-9; author reply e521-e522. PMID: 20660824.
      View in: PubMed
    85. Chien CP, Roach M. Who, when, where, and how: salvage prostate cancer with radiotherapy. Oncology (Williston Park). 2010 Jul; 24(8):702, 704. PMID: 20718249.
      View in: PubMed
    86. Westphalen AC, Coakley FV, Roach M, McCulloch CE, Kurhanewicz J. Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology. 2010 Aug; 256(2):485-92. PMID: 20551184; PMCID: PMC2909433.
    87. Roach M, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H. Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1314-22. PMID: 20378270; PMCID: PMC2920356.
    88. Roach M, Nam J, Gagliardi G, El Naqa I, Deasy JO, Marks LB. Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3 Suppl):S130-4. PMID: 20171507; PMCID: PMC4786051.
    89. Roach M. Prostate cancer: worse sexual function after cryoablation--a case for EBRT? Nat Rev Urol. 2010 Mar; 7(3):122-4. PMID: 20220752.
      View in: PubMed
    90. Hossain S, Xia P, Huang K, Descovich M, Chuang C, Gottschalk AR, Roach M, Ma L. Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Sep 01; 78(1):58-63. PMID: 20133073.
      View in: PubMed
    91. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2):162-200. PMID: 20141676.
      View in: PubMed
    92. Jabbari S, Weinberg VK, Shinohara K, Speight JL, Gottschalk AR, Hsu IC, Pickett B, McLaughlin PW, Sandler HM, Roach M. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys. 2010 Jan 01; 76(1):36-42. PMID: 19409729.
      View in: PubMed
    93. Michalski JM, Bae K, Roach M, Markoe AM, Sandler HM, Ryu J, Parliament MB, Straube W, Valicenti RK, Cox JD. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys. 2010 Jan 01; 76(1):14-22. PMID: 19577865; PMCID: PMC2795116.
    94. Roach M. Editorial comment. J Urol. 2010 Feb; 183(2):551. PMID: 20006855.
      View in: PubMed
    95. Roach M. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era: change you can believe in, or back to the future? (In regard to Nguyen PL, et al. (Int J Radiat Oncol Biol Phys 2009). Int J Radiat Oncol Biol Phys. 2009 Sep 01; 75(1):316; author reply 316. PMID: 19695446.
      View in: PubMed
    96. Konski A, James J, Hartsell W, Leibenhaut MH, Janjan N, Curran W, Roach M, Watkins-Bruner D. Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases. Am J Clin Oncol. 2009 Aug; 32(4):423-8. PMID: 19546803; PMCID: PMC2941643.
    97. Chow E, James J, Barsevick A, Hartsell W, Ratcliffe S, Scarantino C, Ivker R, Roach M, Suh J, Petersen I, Konski A, Demas W, Bruner D. Functional interference clusters in cancer patients with bone metastases: a secondary analysis of RTOG 9714. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1507-11. PMID: 19632065; PMCID: PMC2846210.
    98. Roach M, Waldman F, Pollack A. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer. 2009 Jul 01; 115(13 Suppl):3112-20. PMID: 19544539; PMCID: PMC2760302.
    99. Potters L, Roach M, Davis BJ, Stock RG, Ciezki JP, Zelefsky MJ, Stone NN, Fearn PA, Yu C, Shinohara K, Kattan MW. Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable. Int J Radiat Oncol Biol Phys. 2010 Mar 15; 76(4):1061-5. PMID: 19540064.
      View in: PubMed
    100. Jabbari S, Hsu IC, Kawakami J, Weinberg VK, Speight JL, Gottschalk AR, Roach M, Shinohara K. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience. Brachytherapy. 2009 Oct-Dec; 8(4):339-44. PMID: 19428310.
      View in: PubMed
    101. Michalski JM, Roach M, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll PR. ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate. Int J Radiat Oncol Biol Phys. 2009 Jul 01; 74(3):667-72. PMID: 19386445.
      View in: PubMed
    102. Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M, Shinohara K. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int. 2009 Sep; 104(5):600-4. PMID: 19245439.
      View in: PubMed
    103. Roach M. Predicting pathologic stage, nomograms, and clinical judgment: don't miss the forest for the trees! Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):325-6. PMID: 19147013.
      View in: PubMed
    104. Schröder FH, Roach M, Scardino P. Clinical decisions. Management of prostate cancer. N Engl J Med. 2008 Dec 11; 359(24):2605-9. PMID: 19073981.
      View in: PubMed
    105. Lawton CA, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal SA, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M, Pisansky TM, Seider M. Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Jun 01; 74(2):377-82. PMID: 18947941; PMCID: PMC2905162.
    106. Sahgal A, Jabbari S, Chen J, Pickett B, Roach M, Weinberg V, Hsu IC, Pouliot J. Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131 Cs and 125 I for prostate permanent implant brachytherapy. Int J Radiat Oncol Biol Phys. 2008 Sep 01; 72(1):247-54. PMID: 18722275.
      View in: PubMed
    107. Joseph T, McKenna DA, Westphalen AC, Coakley FV, Zhao S, Lu Y, Hsu IC, Roach M, Kurhanewicz J. Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2009 Mar 01; 73(3):665-71. PMID: 18760545; PMCID: PMC2737354.
    108. Roach M. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials. J Clin Oncol. 2008 Aug 01; 26(22):3816-7; author reply 3817-8. PMID: 18669477.
      View in: PubMed
    109. Yu JS, Roach M. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008 Jul 10; 359(2):200; author reply 201-2. PMID: 18614788.
      View in: PubMed
    110. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Shinohara K, Fearn PA, Kattan MW, Stock RG. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):341-6. PMID: 18597953.
      View in: PubMed
    111. Roach M. "Short- and long-term mortality with localized prostate cancer": errors and omissions? Arch Intern Med. 2008 Jun 23; 168(12):1351; author reply 1353. PMID: 18574095.
      View in: PubMed
    112. Hartsell WF, Desilvio M, Bruner DW, Scarantino C, Ivker R, Roach M, Suh J, Demas WF, Movsas B, Petersen IA, Konski AA. Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 97-14. J Palliat Med. 2008 Jun; 11(5):723-8. PMID: 18588404.
      View in: PubMed
    113. Chung HT, Xia P, Chan LW, Park-Somers E, Roach M. Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):53-60. PMID: 18501530.
      View in: PubMed
    114. Chan LW, Xia P, Gottschalk AR, Akazawa M, Scala M, Pickett B, Hsu IC, Speight J, Roach M. Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Sep 01; 72(1):69-77. PMID: 18342454.
      View in: PubMed
    115. Taussky D, Bae K, Bahary JP, Roach M, Lawton CA, Shipley WU, Sandler HM. Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413. Urology. 2008 Nov; 72(5):1125-9. PMID: 18314175.
      View in: PubMed
    116. D'Ambrosio DJ, Pollack A, Harris EE, Price RA, Verhey LJ, Roach M, Demanes DJ, Steinberg ML, Potters L, Wallner PE, Konski A. Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Mar 01; 70(3):671-7. PMID: 18262085.
      View in: PubMed
    117. McKenna DA, Coakley FV, Westphalen AC, Zhao S, Lu Y, Webb EM, Pickett B, Roach M, Kurhanewicz J. Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience. Radiology. 2008 Apr; 247(1):141-6. PMID: 18258811; PMCID: PMC3694427.
    118. Shinohara K, Roach M. Technique for implantation of fiducial markers in the prostate. Urology. 2008 Feb; 71(2):196-200. PMID: 18308082.
      View in: PubMed
    119. Roach M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008 Feb 01; 26(4):585-91. PMID: 18172188.
      View in: PubMed
    120. Lometti MW, Thurston D, Aubin M, Bock A, Verhey L, Lockhart JM, Bland R, Pouliot J, Roach M. Are lateral electronic portal images adequate for accurate on-line daily targeting of the prostate? Results of a prospective study. Med Dosim. 2008; 33(1):22-9. PMID: 18262119.
      View in: PubMed
    121. Sahgal A, Roach M. Permanent prostate seed brachytherapy: a current perspective on the evolution of the technique and its application. Nat Clin Pract Urol. 2007 Dec; 4(12):658-70. PMID: 18059346.
      View in: PubMed
    122. Roach M. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both? Strahlenther Onkol. 2007 Dec; 183 Spec No 2:26-8. PMID: 18167004.
      View in: PubMed
    123. Ludlum E, Mu G, Weinberg V, Roach M, Verhey LJ, Xia P. An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodes. Med Phys. 2007 Dec; 34(12):4750-6. PMID: 18196802.
      View in: PubMed
    124. Ludlum E, Mu G, Weinberg V, Roach M, Verhey LJ, Xia P. An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodesa). Med Phys. 2007 Dec; 34(12):4750-4756. PMID: 28523810.
      View in: PubMed
    125. Roach M. Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk? J Clin Oncol. 2007 Nov 20; 25(33):5325-6; author reply 5326. PMID: 18024880.
      View in: PubMed
    126. Roach M. Editorial comment on: high provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. Eur Urol. 2008 Jul; 54(1):105-6. PMID: 17997012.
      View in: PubMed
    127. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Fearn PA, Kattan MW, Stock RG. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1472-7. PMID: 17689026.
      View in: PubMed
    128. Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M, Sandler H, Shrieve D, Srinivas S, Twardowski P, Urban DA, Walsh PC. Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Aug; 5(7):650-83. PMID: 17692170.
      View in: PubMed
    129. Zapotoczna A, Sasso G, Simpson J, Roach M. Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer. Neoplasia. 2007 Jun; 9(6):455-63. PMID: 17603627; PMCID: PMC1899254.
    130. Lawton CA, DeSilvio M, Roach M, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007 Nov 01; 69(3):646-55. PMID: 17531401; PMCID: PMC2917177.
    131. Litzenberg DW, Willoughby TR, Balter JM, Sandler HM, Wei J, Kupelian PA, Cunningham AA, Bock A, Aubin M, Roach M, Shinohara K, Pouliot J. Positional stability of electromagnetic transponders used for prostate localization and continuous, real-time tracking. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1199-206. PMID: 17513060.
      View in: PubMed
    132. Roach M, De Silvio M, Rebbick T, Grignon D, Rotman M, Wolkov H, Fisher B, Hanks G, Shipley WU, Pollack A, Sandler H, Watkins-Bruner D. Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2007 Sep 01; 69(1):79-87. PMID: 17498886.
      View in: PubMed
    133. Speight JL, Roach M. Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy. J Clin Oncol. 2007 Mar 10; 25(8):987-95. PMID: 17350948.
      View in: PubMed
    134. Roach M, Izaguirre A. Goserelin acetate in combination with radiotherapy for prostate cancer. Expert Opin Pharmacother. 2007 Feb; 8(2):257-64. PMID: 17257094.
      View in: PubMed
    135. Bermudez RS, Izaguirre A, Roach M. State-of-the-art radiotherapy in the management of clinically localized prostate carcinoma. Future Oncol. 2007 Feb; 3(1):103-11. PMID: 17280507.
      View in: PubMed
    136. Schiffner DC, Gottschalk AR, Lometti M, Aubin M, Pouliot J, Speight J, Hsu IC, Shinohara K, Roach M. Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):610-9. PMID: 17236978.
      View in: PubMed
    137. Roach M, Weinberg V, Sandler H, Thompson I. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer. 2007 Jan 15; 109(2):213-20. PMID: 17167758.
      View in: PubMed
    138. Frank SJ, Grimm PD, Sylvester JE, Merrick GS, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M, Clarke DH, Stock RG, Robert Lee W, Michalski JM, Wallner KE, Hurwitz M, Potters L, Kuban DA, Prestidge BR, Vera R, Hathaway S, Blasko JC. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy. 2007 Jan-Mar; 6(1):2-8. PMID: 17284379.
      View in: PubMed
    139. Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M, Hsu IC. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. 2007 Mar 15; 67(4):1106-12. PMID: 17197119.
      View in: PubMed
    140. Roach M, Weinberg V, Nash M, Sandler HM, McLaughlin PW, Kattan MW. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials. J Urol. 2006 Dec; 176(6 Pt 2):S16-20. PMID: 17084158.
      View in: PubMed
    141. Roach M, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, Thomas CR, Shipley WU. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):647-53. PMID: 17011443.
      View in: PubMed
    142. Wang-Chesebro A, Xia P, Coleman J, Akazawa C, Roach M. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):654-62. PMID: 17011444.
      View in: PubMed
    143. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):965-74. PMID: 16798415.
      View in: PubMed
    144. Willoughby TR, Kupelian PA, Pouliot J, Shinohara K, Aubin M, Roach M, Skrumeda LL, Balter JM, Litzenberg DW, Hadley SW, Wei JT, Sandler HM. Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Jun 01; 65(2):528-34. PMID: 16690435.
      View in: PubMed
    145. Speight JL, Roach M. Radiotherapy in the management of common genitourinary malignancies. Hematol Oncol Clin North Am. 2006 Apr; 20(2):321-46. PMID: 16730297.
      View in: PubMed
    146. Pickett B, Kurhanewicz J, Pouliot J, Weinberg V, Shinohara K, Coakley F, Roach M. Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int J Radiat Oncol Biol Phys. 2006 May 01; 65(1):65-72. PMID: 16517094.
      View in: PubMed
    147. Abdel-Wahab M, Berkey BA, Krishan A, O'Brien T, Hammond E, Roach M, Lawton C, Pilepich M, Markoe A, Pollack A. Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Am J Clin Oncol. 2006 Feb; 29(1):14-20. PMID: 16462497.
      View in: PubMed
    148. Shipley WU, Desilvio M, Pilepich MV, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys. 2006 Mar 15; 64(4):1162-7. PMID: 16427211.
      View in: PubMed
    149. Morin O, Gillis A, Chen J, Aubin M, Bucci MK, Roach M, Pouliot J. Megavoltage cone-beam CT: system description and clinical applications. Med Dosim. 2006; 31(1):51-61. PMID: 16551529.
      View in: PubMed
    150. Speight JL, Roach M. New techniques and management options for localized prostate cancer. Rev Urol. 2006; 8 Suppl 2:S22-9. PMID: 17021638; PMCID: PMC1578718.
    151. Soloway M, Roach M. Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era. Cancer. 2005 Dec 01; 104(11):2310-22. PMID: 16222694.
      View in: PubMed
    152. Speight JL, Roach M. Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol. 2005 Nov 10; 23(32):8176-85. PMID: 16278470.
      View in: PubMed
    153. Roach M. Radiotherapy plus adjuvant goserelin improves survival in men with poor prognosis prostate cancer. Cancer Treat Rev. 2005 Nov; 31(7):582-6. PMID: 16256275.
      View in: PubMed
    154. Roach M. Commentary on increased risk of biochemical and local failure in patients with a distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jul 15; 62(4):949-50. PMID: 15989992.
      View in: PubMed
    155. Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach M, Bosch W, Cox JD. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys. 2005 Jul 01; 62(3):706-13. PMID: 15936549.
      View in: PubMed
    156. Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005 Jun 01; 97(11):798-804. PMID: 15928300.
      View in: PubMed
    157. Morris DE, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, Klein EA, Mohideen N, Hurwitz MD, Fraas BA, Roach M, Gore EM, Tepper JE. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys. 2005 May 01; 62(1):3-19. PMID: 15850897.
      View in: PubMed
    158. Bucci MK, Bevan A, Roach M. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin. 2005 Mar-Apr; 55(2):117-34. PMID: 15761080.
      View in: PubMed
    159. Pouliot J, Bani-Hashemi A, Chen J, Svatos M, Ghelmansarai F, Mitschke M, Aubin M, Xia P, Morin O, Bucci K, Roach M, Hernandez P, Zheng Z, Hristov D, Verhey L. Low-dose megavoltage cone-beam CT for radiation therapy. Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):552-60. PMID: 15736320.
      View in: PubMed
    160. Andrews J, Roach M. Integrating hormonal therapy with external-beam radiation and brachytherapy for prostate cancer. Oncology (Williston Park). 2005 Jan; 19(1):29-36; discussion 36, 39, 43-4. PMID: 15743150.
      View in: PubMed
    161. Roach M. Is it time to change the standard of care from CT to MRI for defining the apex of the prostate to accomplish potency-sparing radiotherapy? Int J Radiat Oncol Biol Phys. 2005 Jan 01; 61(1):1-2. PMID: 15629584.
      View in: PubMed
    162. Hsu IC, Cabrera AR, Weinberg V, Speight J, Gottschalk AR, Roach M, Shinohara K. Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer. Brachytherapy. 2005; 4(3):202-6. PMID: 16182220.
      View in: PubMed
    163. Roach M, Winter K, Michalski JM, Cox JD, Purdy JA, Bosch W, Lin X, Shipley WS. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1351-6. PMID: 15590164.
      View in: PubMed
    164. Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Nov 15; 60(4):1047-55. PMID: 15519774.
      View in: PubMed
    165. Liu YM, Ling S, Langen KM, Shinohara K, Weinberg V, Pouliot J, Roach M. Prostate movement during simulation resulting from retrograde urethrogram compared with "natural" prostate movement. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):470-5. PMID: 15380581.
      View in: PubMed
    166. Coakley FV, Teh HS, Qayyum A, Swanson MG, Lu Y, Roach M, Pickett B, Shinohara K, Vigneron DB, Kurhanewicz J. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology. 2004 Nov; 233(2):441-8. PMID: 15375223.
      View in: PubMed
    167. Zelefsky MJ, Moughan J, Owen J, Zietman AL, Roach M, Hanks GE. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1053-61. PMID: 15234039.
      View in: PubMed
    168. Pickett B, Ten Haken RK, Kurhanewicz J, Qayyum A, Shinohara K, Fein B, Roach M. Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys. 2004 Jul 01; 59(3):665-73. PMID: 15183469.
      View in: PubMed
    169. Li R, Heydon K, Hammond ME, Grignon DJ, Roach M, Wolkov HB, Sandler HM, Shipley WU, Pollack A. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4118-24. PMID: 15217948.
      View in: PubMed
    170. Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M, Shipley WU, Hanks GE, Sandler HM. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol. 2004 Jun 01; 22(11):2133-40. PMID: 15169799.
      View in: PubMed
    171. Roach M. Treatment margins and prostate brachytherapy: "size matters," but how much and where? Cancer J. 2004 May-Jun; 10(3):158-9. PMID: 15285924.
      View in: PubMed
    172. Millender LE, Aubin M, Pouliot J, Shinohara K, Roach M. Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):6-10. PMID: 15093893.
      View in: PubMed
    173. Roach M. Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer. Urol Clin North Am. 2004 May; 31(2):353-66. PMID: 15123413.
      View in: PubMed
    174. Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M, Sandler HM, Markoe AM, Cox JD. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys. 2004 Mar 01; 58(3):735-42. PMID: 14967428.
      View in: PubMed
    175. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 01; 22(3):537-56. PMID: 14752077.
      View in: PubMed
    176. Roach M. Neoadjuvant hormonal therapy in men being treated with radiotherapy for localized prostate cancer. Rev Urol. 2004; 6 Suppl 8:S24-31. PMID: 16985917; PMCID: PMC1472897.
    177. Roach M. Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long? J Urol. 2003 Dec; 170(6 Pt 2):S35-40; discussion S40-1. PMID: 14610408.
      View in: PubMed
    178. Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, Kantoff PW. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol. 2003 Dec; 170(6 Pt 2):S3-5. PMID: 14610403.
      View in: PubMed
    179. Roach M. Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: "love the one you're with" and "do the right thing". Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):907-9. PMID: 14575819.
      View in: PubMed
    180. Takamiya R, Weinberg V, Young CD, Sandler H, McLaughlin P, Roach M. A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003 Jul 15; 56(4):1073-8. PMID: 12829144.
      View in: PubMed
    181. Pouliot J, Aubin M, Langen KM, Liu YM, Pickett B, Shinohara K, Roach M. (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. Int J Radiat Oncol Biol Phys. 2003 Jul 01; 56(3):862-6. PMID: 12788196.
      View in: PubMed
    182. Michalski JM, Winter K, Purdy JA, Wilder RB, Perez CA, Roach M, Parliament MB, Pollack A, Markoe AM, Harms W, Sandler HM, Cox JD. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):192-8. PMID: 12694838.
      View in: PubMed
    183. Roberts T, Roach M. The evolving role of pelvic radiation therapy. Semin Radiat Oncol. 2003 Apr; 13(2):109-20. PMID: 12728440.
      View in: PubMed
    184. Roach M. "Supplemental beam" and prostate brachytherapy: a simple answer to a complicated question? Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1162-3. PMID: 12654420.
      View in: PubMed
    185. Roach M, Weinberg V, McLaughlin PW, Grossfeld G, Sandler HM. Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate. Urology. 2003 Apr; 61(4):730-5. PMID: 12670556.
      View in: PubMed
    186. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol. 2003 Jan; 169(1):245-50. PMID: 12478146.
      View in: PubMed
    187. Heron DE, Godette KD, Wynn RA, Arterbery VE, Streeter OA, Roach M, Simpson JR, Blough M, Thomas CR. Radiation medicine innovations for the new millenium. J Natl Med Assoc. 2003 Jan; 95(1):55-63. PMID: 12656450; PMCID: PMC2594374.
    188. Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA, Machtay M. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys. 2002 Dec 01; 54(5):1302-10. PMID: 12459350.
      View in: PubMed
    189. Lee TT, Everett DL, Shu HK, Jahan TM, Roach M, Speight JL, Cameron RB, Phillips TL, Chan A, Jablons DM. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2002 Dec; 124(6):1183-9. PMID: 12447185.
      View in: PubMed
    190. Ryu JK, Winter K, Michalski JM, Purdy JA, Markoe AM, Earle JD, Perez CA, Roach M, Sandler HM, Pollack A, Cox JD. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys. 2002 Nov 15; 54(4):1036-46. PMID: 12419429.
      View in: PubMed
    191. Lee WR, Roach M, Michalski J, Moran B, Beyer D. Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):457-61. PMID: 12243822.
      View in: PubMed
    192. Roach M. Radical prostatectomy or external beam radiotherapy: one step forward or two steps back? Cancer. 2002 Jul 15; 95(2):215-8. PMID: 12124818.
      View in: PubMed
    193. Pirzkall A, Carol MP, Pickett B, Xia P, Roach M, Verhey LJ. The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets. Int J Radiat Oncol Biol Phys. 2002 Jun 01; 53(2):434-42. PMID: 12023148.
      View in: PubMed
    194. Small EJ, Roach M. Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Semin Oncol. 2002 Jun; 29(3):264-73. PMID: 12063679.
      View in: PubMed
    195. Michalski JM, Winter K, Purdy JA, Wilder R, Perez CA, Roach M, Parliament M, Pollack A, Markoe A, Harms WB, Sandler H, Cox JD. Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. Semin Radiat Oncol. 2002 Jan; 12(1 Suppl 1):75-80. PMID: 11917289.
      View in: PubMed
    196. Jani AB, Vaida F, Hanks G, Asbell S, Sartor O, Moul JW, Roach M, Brachman D, Kalokhe U, Muller-Runkel R, Ray P, Ignacio L, Awan A, Weichselbaum RR, Vijayakumar S. Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 2001 Dec 20; 96(6):363-71. PMID: 11745507.
      View in: PubMed
    197. Campbell T, Blasko J, Crawford ED, Forman J, Hanks G, Kuban D, Montie J, Moul J, Pollack A, Raghavan D, Ray P, Roach M, Steinberg G, Stone N, Thompson I, Vogelzang N, Vijayakumar S. Clinical staging of prostate cancer: reproducibility and clarification of issues. Int J Cancer. 2001 Jun 20; 96(3):198-209. PMID: 11410889.
      View in: PubMed
    198. Watkins Bruner D, Berk L, Bondy M, Kachnic LA, Konski A, Layne E, Lee WR, Choucair A, Movsas B, Okunieff P, Roach M, Scott C, Vijayakumar S, Wenzel L. Radiation Therapy Oncology Group. Research Plan 2002-2006. Outcomes Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):66-74. PMID: 11641019.
      View in: PubMed
    199. Sandler H, Shipley WU, Gomella L, Pienta K, Bard RH, Bruner D, Clark R, DeSilvio M, Gaspar L, Gillin M, Grignon D, Hammond E, Hanks G, Heydon KH, Kaufman DS, Lee WR, Michalski J, Mydlo J, Pisansky T, Pollack A, Porterfield H, Rifkin M, Roach M, Sanda M, True L, Vijayakumar S, Winter KA, Zeitman A. Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):28-38. PMID: 11641012.
      View in: PubMed
    200. Bahnson RR, Hanks GE, Huben RP, Kantoff P, Kozlowski JM, Kuettel M, Lange PH, Logothetis C, Pow-Sang JM, Roach M, Sandler H, Scardino PT, Taylor RJ, Urban DA, Walsh PC, Wilson TG. NCCN Practice Guidelines for Prostate Cancer. Oncology (Williston Park). 2000 Nov; 14(11A):111-9. PMID: 11195405.
      View in: PubMed
    201. Roach M. Three-dimensional conformal external beam radiotherapy or brachytherapy: which is the "best alternative" to radical prostatectomy? CA Cancer J Clin. 2000 Nov-Dec; 50(6):344-7. PMID: 11188755.
      View in: PubMed
    202. Roach M, Hsu I. Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present. Urology. 2000 Sep 01; 56(3):439-40. PMID: 10962310.
      View in: PubMed
    203. Wilder RB, Chou RH, Ryu JK, Stern RL, Wong MS, Ji M, Roach M, White RD. Potency preservation after three-dimensional conformal radiotherapy for prostate cancer: preliminary results. Am J Clin Oncol. 2000 Aug; 23(4):330-3. PMID: 10955856.
      View in: PubMed
    204. Forman JD, Lee WR, Roach M, Perez CA, Beyer DC, Blasko JC, Hussey DH, Paryani SB, Pollack A, Potters L, Scardino P, Schellhammer P, Leibel S. Staging evaluation for patients with adenocarcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun; 215 Suppl:1373-82. PMID: 11037553.
      View in: PubMed
    205. Potters L, Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Lee WR, Paryani SB, Pollack A, Roach M, Scardino P, Schellhammer P, Leibel S. Permanent source brachytherapy for prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun; 215 Suppl:1383-400. PMID: 11037554.
      View in: PubMed
    206. Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Lee WR, Paryani SB, Pollack A, Potters L, Roach M, Scardino P, Schellhammer P, Leibel S. Postradical prostatectomy irradiation in carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun; 215 Suppl:1419-39. PMID: 11037557.
      View in: PubMed
    207. Pollack A, Paryani SB, Hussey D, Perez CA, Beyer DC, Blasko JC, Forman JD, Lee WR, Potters L, Roach M, Scardino P, Schellhammer P, Leibel S. Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun; 215 Suppl:1401-12. PMID: 11037555.
      View in: PubMed
    208. Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Lee WR, Paryani SB, Pollack A, Potters L, Roach M, Scardino P, Schellhammer P, Leibel S. Definitive external beam irradiation in stage T1 and T2 carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun; 215 Suppl:1449-72. PMID: 11037559.
      View in: PubMed
    209. Lee WR, Pollack A, Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Paryani SB, Potters L, Roach M, Scardino P, Schellhammer P, Leibel S. Node-positive prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun; 215 Suppl:1413-8. PMID: 11037556.
      View in: PubMed
    210. Weil MD, Crawford ED, Cornish P, Dzingle W, Stuhr K, Pickett B, Roach M. Minimal toxicity with 3-FAT radiotherapy of prostate cancer. Semin Urol Oncol. 2000 May; 18(2):127-32. PMID: 10875453.
      View in: PubMed
    211. Michalski JM, Purdy JA, Winter K, Roach M, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys. 2000 Jan 15; 46(2):391-402. PMID: 10661346.
      View in: PubMed
    212. Roach M, Reese D, Weinberg V, Small EJ, Carroll PR. Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer? J Clin Oncol. 2000 Jan; 18(2):448-50. PMID: 10637263.
      View in: PubMed
    213. Streeter OE, Martz KL, Gaspar LE, Delrowe JD, Asbell SO, Salter MM, Roach M. Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01? Int J Radiat Oncol Biol Phys. 1999 Jul 15; 44(5):1047-52. PMID: 10421537.
      View in: PubMed
    214. Roach M, Forte D, Alexander M. Re: Race, prostate cancer survival, and membership in a large health maintenance organization. J Natl Cancer Inst. 1999 May 05; 91(9):801-3. PMID: 10328112.
      View in: PubMed
    215. Werner-Wasik M, Scott C, Graham ML, Smith C, Byhardt RW, Roach M, Andras EJ. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients. Int J Radiat Oncol Biol Phys. 1999 May 01; 44(2):327-31. PMID: 10760427.
      View in: PubMed
    216. Roach M. Management of locally advanced prostate cancer: new definitions and strategies. West J Med. 1998 Nov; 169(5):290-1. PMID: 9830363; PMCID: PMC1305325.
    217. Bice WS, Prestidge BR, Grimm PD, Friedland JL, Feygelman V, Roach M, Prete JJ, Dubois DF, Blasko JC. Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1998 Jul 01; 41(4):921-7. PMID: 9652858.
      View in: PubMed
    218. Chamberlain RM, Winter KA, Vijayakumar S, Porter AT, Roach M, Streeter O, Cox JD, Bondy ML. Sociodemographic analysis of patients in radiation therapy oncology group clinical trials. Int J Radiat Oncol Biol Phys. 1998 Jan 01; 40(1):9-15. PMID: 9422552.
      View in: PubMed
    219. Wilder RB, Fone PD, Rademacher DE, Jones CD, Roach M, Earle JD, White RD. Localization of the prostatic apex for radiotherapy treatment planning using urethroscopy. Int J Radiat Oncol Biol Phys. 1997 Jul 01; 38(4):737-41. PMID: 9240640.
      View in: PubMed
    220. Roach M. Comparison of treatment techniques for conformal radiotherapy of the prostate using dose-volume histograms and normal tissue complication probabilities. Radiother Oncol. 1996 Jul; 40(1):85-7. PMID: 8844893.
      View in: PubMed
    221. Roach M, Holland J, Chan A, Shrieve D. Markers, CTs, urethrograms, and the prostatic apex. Int J Radiat Oncol Biol Phys. 1995 Jan 01; 31(1):207-9. PMID: 7995762.
      View in: PubMed
    222. Sherebrin MH, Kim HL, Roach MR. Calcium mass in human aortas from autopsy. Physiol Meas. 1994 Aug; 15(3):281-9. PMID: 7994206.
      View in: PubMed
    223. Thomas CR, Pinto HA, Roach M, Vaughn CB. Participation in clinical trials: is it state-of-the-art treatment for African Americans and other people of color? J Natl Med Assoc. 1994 Mar; 86(3):177-82. PMID: 8189450; PMCID: PMC2568186.
    224. Roach M, Akazawa PF, Pickett B, Purser P, Parkinson D, Meyler TS, Margolis LW. Bilateral arcs using "averaged beam's eye views": a simplified technique for delivering 3-D based conformal radiotherapy. Med Dosim. 1994; 19(3):159-68. PMID: 7818756.
      View in: PubMed
    225. Komaki R, Pajak TF, Byhardt RW, Emami B, Asbell SO, Roach M, Pedersen JE, Curran WJ, Lattin P, Russell AH. Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433. Lung Cancer. 1993 Dec; 10(3-4):189-97. PMID: 8075966.
      View in: PubMed
    226. Roach M. Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993 Dec; 150(6):1923-4. PMID: 7693984.
      View in: PubMed
    227. Cox JD, Pajak TF, Asbell S, Russell AH, Pederson J, Byhardt RW, Emami B, Roach M. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys. 1993 Oct 20; 27(3):493-8. PMID: 8226140.
      View in: PubMed
    228. Vijayakumar S, Roach M, Wara W, Chan SK, Ewing C, Rubin S, Sutton H, Halpern H, Awan A, Houghton A. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial. Int J Radiat Oncol Biol Phys. 1993 Jul 15; 26(4):721-9. PMID: 8331011.
      View in: PubMed
    229. Graham MV, Geitz LM, Byhardt R, Asbell S, Roach M, Urtasun RC, Curran WJ, Lattin P, Russell AH, Cox JD. Comparison of prognostic factors and survival among black patients and white patients treated with irradiation for non-small-cell lung cancer. J Natl Cancer Inst. 1992 Nov 18; 84(22):1731-5. PMID: 1331484.
      View in: PubMed
    230. Roach M, Alexander M, Coleman JL. The prognostic significance of race and survival from laryngeal carcinoma. J Natl Med Assoc. 1992 Aug; 84(8):668-74. PMID: 1507256; PMCID: PMC2571639.
    231. Holdsworth DW, Dunmore PJ, Roach M, Fenster A. A digital-radiographic technique for in vitro tissue thickness measurement using iodine displacement. Med Phys. 1992 May-Jun; 19(3):545-54. PMID: 1508088.
      View in: PubMed
    232. Roach M, Alexander M, Coleman JL. Race and survival from intracranial ependymomas in children. Int J Radiat Oncol Biol Phys. 1991 Nov; 21(6):1675-6. PMID: 1938578.
      View in: PubMed
    233. Gandara DR, Valone FH, Perez EA, Deisseroth AB, Roach M, Ahn DK, Phillips T. Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study. Int J Radiat Oncol Biol Phys. 1991 May; 20(5):1047-52. PMID: 1850719.
      View in: PubMed
    234. Roach M, Brophy N, Cox R, Varghese A, Hoppe RT. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol. 1990 Apr; 8(4):623-9. PMID: 2313331.
      View in: PubMed
    Mack's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP